Executive Summary

Investment Thesis: TPST is a small-cap biotechnology company focused on oncology therapies, showing recent progress with a pivotal trial clearance in China and a manufacturing tech-transfer partnership for a CAR-T candidate. Those program-level wins have produced analyst enthusiasm, reflected in a strong buy consensus, but the balance sheet is thin and management has recently raised capital, which increases dilution risk. Given the binary nature of clinical readouts and the lack of revenue, price action is likely to remain driven by clinical and financing headlines.

Current Price: $2.26 | Key Metric: Market Cap $12.27M | Stance: NEUTRAL

Company Overview

TPST (Tempest Therapeutics) is a clinical-stage biotechnology company in the oncology space, pursuing both small molecule and cell therapy programs. The company recently added dual-targeting CAR-T assets and is advancing other pipeline programs through strategic partnerships and registered offerings.

Key Products & Competitive Position

Core Business: Discovery and development of oncology therapeutics, including CAR-T programs and combination therapy candidates.
Key Products: Amezalpat combination therapy for hepatocellular carcinoma (HCC), TPST-2003 CAR-T candidate for relapsed/refractory multiple myeloma, and recently acquired dual-targeting CAR-T assets.
Competitive Moat: Scientific position is dependent on proprietary biology and CAR-T constructs, but the company is early stage with limited commercial differentiation until clinical validation.

Recent Developments

Notable recent activity includes clearance to proceed with a pivotal Amezalpat combination trial in China, selection of Cincinnati Childrens AGCTC to handle tech transfer and IND-enabling manufacturing for TPST-2003, closing of a strategic acquisition of dual-targeting CAR-T assets, and a $4.6 million registered direct offering. These moves accelerate development but raise near-term financing questions.

Financial Snapshot

Market Cap$12.27M

P/E Ratio--

52-Week Range$2.22 - $70.72

Dividend Yield0.0%

EPS (TTM)-$9.73

ROE-405.03%

Revenue & Earnings Trends

TPST is a clinical-stage biotech with no meaningful product revenue reported. The trailing twelve-months diluted EPS is negative $9.73 and net income attributable to common shareholders shows a sizable loss (about -$36.05M TTM). Quarterly results are driven by R&D and G&A spending as pipeline programs progress. Expect ongoing negative earnings until a commercial product or partnering milestone generates revenue.

Balance Sheet Highlights

The company reported approximately $7.51M in cash at the most recent disclosure and an enterprise value near $13.16M. Total debt to equity is elevated at about 132% on reported metrics, which suggests leverage or financing arrangements that materially affect solvency risk for such a small issuer. Management has completed a $4.6M registered direct offering, which extends runway but also dilutes shareholders.

Valuation Analysis

Current Valuation Metrics

Forward P/E--vs Industry: --

PEG Ratio--Growth-adjusted

EV/EBITDA--vs Historical: --

P/S Ratio--vs Peers: --

Historical Comparison

TPST traded as high as $70.72 over the trailing 52-week window, but recent prices near $2 reflect a dramatic contraction after clinical or financing events that removed earlier optimism. Current market capitalization implies the market is pricing in significant execution risk and a low probability of late-stage commercial success absent further positive catalysts.

Fair Value Estimate

Given the lack of revenue and substantial binary clinical risk, a DCF is not meaningful. A scenario-based approach is more useful. If key trials progress and partnerships or asset monetization occur, implied mid-term valuation could move into low- to mid-single-digit multiples of current market cap. Conversely, failed readouts or an inability to secure additional capital would likely compress value further. For context, a base-case scenario that assumes one partnered program reaches a value-inflection could imply a fair value materially higher than current price, while a fail-or-dilute scenario implies lower valuation.

Competitive Landscape

Market Position

Market Share: N/A | Ranking: Early-stage player in oncology biotechs

Key Competitors

$CARVCell and gene therapy focused biotech with CAR-T programs

$KITELarge established CAR-T developer, market leader in certain indications

$JNJMajor pharmaceutical company with oncology immunotherapy portfolio

Competitive Advantages

Moat 1: Proprietary CAR-T constructs and acquired dual-targeting assets that may offer differentiation if clinical data support improved durability.
Moat 2: Strategic manufacturing partnership with a reputable academic center, which may lower development execution risk for IND-enabling work.
Moat 3: Focused pipeline allows management to allocate scarce resources to a few high-conviction programs.

Earnings Track Record

Last 4 Quarters: N/A / N/A

Recent Earnings History

Q4 2025Expected 2026-03-25 After MarketEXPECTED

Q3 2025Reported, no material revenueN/A

Q2 2025Reported, R&D spend driving lossN/A

Q1 2025Reported, pipeline updatesN/A

Guidance Trend

Management has not provided revenue guidance as the company is pre-revenue. The key near-term guidance items are program milestones, IND-enabling activities and timelines for pivotal trial starts, particularly the Amezalpat pivotal trial in China and manufacturing transfer for TPST-2003.

Analyst Sentiment

Consensus Rating: Strong Buy

Strong Buy: 2 Buy: 4 Hold: 1 Sell: 0

Price Targets

Low: N/A
Mean: N/A (N/A)
High: N/A

Recent Analyst Actions

Several analysts have expressed bullish views following the pivotal trial clearance and asset acquisition. The strong buy consensus reflects optimism about the pipeline, but analysts also point to financing and execution risk as important qualifiers to upside estimates.

Recent News & Catalysts

Key Developments

Pivotal Trial Clearance: TPST received clearance to proceed with a pivotal trial of Amezalpat combination therapy in China, an important step toward potential registration in that market.
Tech-Transfer Partnership: Cincinnati Childrens AGCTC selected to conduct formal tech transfer and IND-enabling manufacturing activities for TPST-2003, advancing readiness for clinical trials.
Capital Raise: The company announced a $4.6 million registered direct offering to bolster the balance sheet and support program advancement.

Upcoming Catalysts

Next Earnings: Q4 2025 expected 2026-03-25 After Market | Key Events: Amezalpat pivotal trial start timing, IND-enabling milestones for TPST-2003, updates on integration of the acquired CAR-T assets, and capital plan disclosures.

Technical Outlook

Current Price: $2.26 vs 52-Week High: $70.72 (-96.8% from high)

Trend Analysis

The near-term technical trend is depressed, with the stock trading very near its multi-month lows. Trading volume has historically been uneven, and price moves are frequently headline-driven. You should expect volatility around clinical and financing news. How the market interprets upcoming trial and manufacturing progress will determine directional momentum.

Key Levels

Resistance: $3.50, $5.00
Support: $2.20, $1.50

Bull vs Bear Case

Bull Case

Catalyst 1: Successful start and early readouts from the Amezalpat pivotal program in China, which could validate the asset and attract partners.
Catalyst 2: Positive IND-enabling data and successful tech transfer for TPST-2003 accelerate CAR-T trials and make the asset attractive to partners or acquirers.
Catalyst 3: If the company secures non-dilutive partnerships or milestone payments, implied valuation could expand from current depressed levels.

Bull Target: $6.00 (+165%)

Bear Case

Risk 1: Clinical setbacks or slow enrollment would significantly reduce perceived asset value, given the company's small scale.
Risk 2: Cash runway may force repeated dilutive financings that materially reduce per-share value.
Risk 3: Competition from larger, better-capitalized CAR-T and oncology developers could limit partner interest and commercial prospects.

Bear Target: $1.00 (-56%)

Risks to Consider

Valuation Risk: The market currently prices a low probability of success. Any disappointment will likely trigger outsized downside given the tiny market cap and thin liquidity.
Competitive Risk: TPST operates in an intensely competitive oncology field with larger players that can outspend or out-license technologies.
Macro Risk: Biotech financing markets can tighten quickly, making follow-on funding expensive or dilutive when milestones slip.
Execution Risk: Manufacturing scale-up, regulatory interactions and trial conduct are complex. Delays or technical hurdles in IND-enabling work could push timelines and raise costs.

Bottom Line

Investment Verdict: NEUTRAL

Data suggests TPST carries both attractive clinical upside and pronounced financing and execution risk. Analysts' bullish consensus reflects confidence in the pipeline, but the company's small cash balance and recent offering mean dilution and headline risk remain primary drivers of near-term performance. The outlook depends on upcoming trial starts, IND-enabling progress and how management communicates the capital plan.

Action Items for Investors

Long-term investors: Monitor clinical milestones, manufacturing tech-transfer progress and partnership announcements to assess the long-term value of acquired CAR-T assets.
Short-term traders: Be prepared for high volatility around earnings, trial-start news and financing announcements. Use tight position sizing and predefined exit rules.
Risk management: Track cash runway disclosures and dilution history, and consider position scaling to reflect binary clinical outcomes.

What to Watch This Week

Any updates or disclosures tied to the Q4 2025 filing expected 2026-03-25 after market.
News on timing or enrollment plans for the Amezalpat pivotal trial in China.
Announcements regarding IND-enabling milestones or manufacturing progress for TPST-2003.

TPST: Clinical Catalysts vs Cash Runway